Cheapest GLP-1 medication in 2026Starting at $69/mo, no insurance needed →

Six concrete signals, all verifiable before you pay. (1) A named pharmacy. A legitimate provider tells you which pharmacy compounds your medication and whether it's a 503A (state-licensed, patient-specific) pharmacy or a 503B (FDA-registered outsourcing facility); a provider that hides the pharmacy name is a red flag. (2) Third-party credentials: LegitScript certification (which verifies the merchant complies with applicable laws and is the standard that lets a telehealth pharmacy advertise on Google and Meta) and PCAB accreditation, awarded by ACHC, which audits a pharmacy against US Pharmacopeia compounding standards USP <795> (non-sterile) and USP <797> (sterile injectables). (3) A Certificate of Analysis (CoA) on the active ingredient, confirming it is true semaglutide or tirzepatide base, not a salt form. (4) A US-licensed prescriber who reviews your history rather than a checkbox form. (5) Transparent, all-in pricing with no bait intro rate. (6) Clear labeling, dosing instructions, and a way to report side effects. Risk signals: no pharmacy named, no prescriber consult, salt-form ingredients, prices that look too good to be true, and dosing 'protocols' that exceed FDA-approved labeling. The FDA warns that compounded drugs are not FDA-approved and are not reviewed by the agency for safety, effectiveness, or quality.

A 503A pharmacy is a traditional, state-licensed pharmacy that compounds a medication for an individual patient based on a specific prescription. A 503B outsourcing facility registers with the FDA, is inspected by the FDA on a risk-based schedule, and follows current Good Manufacturing Practice (CGMP) standards, so it can compound larger batches. Neither produces an FDA-approved drug, but a 503B operates under more federal oversight. When a provider names its pharmacy, you can look up the facility: 503B outsourcing facilities appear on the FDA's public registered-facilities list. Whether a provider uses 503A or 503B, the legitimacy questions are the same: is the pharmacy named, is it accredited, and can you see a Certificate of Analysis on the API?

It's narrowly legal and shrinking. The FDA removed semaglutide and tirzepatide from the drug shortage list in early 2025, which ended the broad enforcement window that had allowed mass compounding. As of 2026, 503A pharmacies may still compound on a patient-specific basis only in limited situations, such as a documented allergy to an inactive ingredient in the brand product or a need for a dose strength that isn't commercially available; the FDA has been explicit that lower cost or greater convenience do not, by themselves, establish a 'clinical need.' For 503B outsourcing facilities, in April 2026 the FDA proposed to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List after finding no clinical need to compound them from bulk substances; the public comment period on that proposal closed July 30, 2026 (Docket FDA-2018-N-3240), after an extension from June 29 via FR 2026-12937. Bottom line: a 'compounded GLP-1' offered purely because it's cheaper, with no patient-specific justification, sits in a legally exposed gray zone. Always confirm a provider's pharmacy and prescriber are operating within these rules.

The FDA has flagged that some compounders use semaglutide sodium or semaglutide acetate, which the agency considers different active ingredients from the semaglutide base used in approved drugs (Ozempic, Wegovy). The FDA has stated there is no evidence these salt forms are safe or effective for this use and no legal basis for using them in compounding. A Certificate of Analysis (CoA) is a lab document from the pharmacy or its API supplier confirming the identity, purity, and potency of the active ingredient in your specific product. A legitimate provider can supply one on request and it should show semaglutide base (or tirzepatide), not a salt form. If a provider can't or won't produce a CoA, treat that as a stop sign.

Two stand out. First, dosing errors: the FDA has reported cases where patients accidentally administered five to twenty times the intended dose after drawing medication from multi-dose vials, often because of confusion between 'units,' milliliters, and milligrams, with some cases requiring hospitalization. Brand pens are pre-measured; compounded vials usually are not, so the burden is on you to measure correctly. Second, the FDA has received adverse-event reports tied to compounded products, including reports involving doses beyond FDA-approved labeling. A legitimate provider mitigates the dosing risk with clear instructions, properly labeled syringes, and prescriber guidance. None of this makes brand-name GLP-1s automatically right for you either, but it explains why we weight clinical oversight and pharmacy transparency heavily in our scoring rather than ranking purely by price. See our full safety center and the per-provider reviews for how each one handles this.

Start with eligibility and oversight, then price. Brand-name Wegovy and Zepbound are FDA-approved, pre-dosed, and increasingly available through manufacturer cash programs (for example, LillyDirect Zepbound) and, for some Medicare Part D members, the Part D coverage pathway. Compounded versions can cost meaningfully less but are not FDA-approved, are legal only in narrow patient-specific circumstances in 2026, and put more responsibility on the provider and pharmacy to get safety right. If you go compounded, only use a provider that names an accredited pharmacy, uses a US-licensed prescriber, and can produce a Certificate of Analysis. Use our scored rankings table above to compare, see /best for our editor-vetted picks by use case, and read the individual /reviews for the pharmacy and prescriber details behind each provider. This is general information, not medical advice; talk to a licensed clinician about what's right for you.